Dogwood Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

CONSOLIDATED STATEMENTS OF CHANGES IN SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)

CONSOLIDATED STATEMENTS OF CHANGES IN SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Preferred Stock Series A Non-Voting Convertible Preferred Stock Tungsten support agreement	Preferred Stock Series A Non-Voting Convertible Preferred Stock Sealbond support agreement	Preferred Stock Series A Non-Voting Convertible Preferred Stock	Preferred Stock Series A-1 Non-Voting Convertible Preferred Stock	Preferred Stock Series A-2 Non-Voting Convertible Preferred Stock	Common Stock Registered Direct Offering	Common Stock At the market offering	Common Stock	Additional Paid-In Capital Registered Direct Offering	Additional Paid-In Capital At the market offering	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Treasury Stock	Registered Direct Offering	Tungsten support agreement	Sealbond support agreement	At the market offering	Total
Increase (Decrease) in Temporary Equity [Roll Forward]
Temporary Equity, Issuance of stock in connection with the acquisition of Pharmagesic																			$ 70,372,634
Temporary Equity, Issuance of stock in connection with the acquisition of Pharmagesic (in shares)																			2,108.3854
Temporary Equity, Transaction costs paid through the issuance of stock																			$ 3,518,623
Temporary Equity, Transaction costs paid through the issuance of stock (in shares)																			105.419
Temporary Equity, Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock																			$ 514,105
Balances, Ending at Dec. 31, 2024																			$ 74,405,362
Balances, Ending (in Shares) at Dec. 31, 2024																			2,213.8044
Balances, Beginning at Dec. 31, 2023								$ 77			$ 65,575,167	$ (61,469,222)		$ (299,128)					$ 3,806,894
Balances, Beginning (in shares) at Dec. 31, 2023								770,317
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Proceeds from issuance of shares, net of fees								$ 34			1,382,136								1,382,170
Proceeds from issuance of shares, net of fees (in shares)								340,000
Issuance of stock in connection with the acquisition of Pharmagesic								$ 21			893,072								893,093
Issuance of stock in connection with the acquisition of Pharmagesic (in shares)								211,383
Transaction costs paid through the issuance of stock								$ 1			44,649								44,650
Transaction costs paid through the issuance of stock (in shares)								10,568
Payout of fractional shares in connection with reverse stock split											(351)								(351)
Payout of fractional shares in connection with reverse stock split (in shares)								(90)
Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock											(514,105)								(514,105)
Share-based compensation expense											476,021								476,021
Net loss												(12,349,724)							(12,349,724)
Accumulated other comprehensive loss													$ (3,862,987)						(3,862,987)
Foreign currency translation adjustment																			(3,862,987)
Balances, Ending at Dec. 31, 2024								$ 133			67,856,589	(73,818,946)	(3,862,987)	(299,128)					(10,124,339)
Balances, Ending (in shares) at Dec. 31, 2024								1,332,178
Increase (Decrease) in Temporary Equity [Roll Forward]
Temporary Equity, Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock																			$ 1,256,662
Temporary Equity, Issuance of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock (in shares)																			55.345
Temporary Equity, Waiver of Series A Non-Voting Convertible Preferred Stock																$ (533,500)	$ (5,001,567)
Temporary Equity, Waiver of Series A Non-Voting Convertible Preferred Stock (in shares)	16	150														(16)	(150)
Temporary Equity, Conversion of preferred stock into common stock																			$ (70,126,957)
Temporary Equity, Conversion of preferred stock into common stock (in shares)																			(2,103.1494)
Balances, Ending (in Shares) at Dec. 31, 2025																			0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of loan payable plus interest into Series A-1 Non-Voting Convertible Preferred Stock				$ 24,994,461															$ 24,994,461
Purchases of common stock warrants				284.2638
Proceeds from issuance of shares, net of fees						$ 58	$ 2		$ 4,252,187	$ 85,249					$ 4,252,245			$ 85,251
Proceeds from issuance of shares, net of fees (in shares)						578,950	15,650
Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock											(1,256,662)								(1,256,662)
Issuance of stock in connection with the License Agreement with Serpin					$ 9,240,328			$ 38			2,108,790								11,349,156
Issuance of stock in connection with the License Agreement with Serpin (in shares)					179.1878			382,034
License Agreement transaction costs paid through the issuance of stock					$ 560,511														560,511
License Agreement transaction costs paid through the issuance of stock (in shares)					10.8694
Waiver and conversion of preferred stock	$ 533,500	$ 5,001,567	$ (5,535,067)	$ (24,994,461)	$ (9,800,839)			$ 2,743			110,454,581					$ 533,500	$ 5,001,567		70,126,957
waiver and Conversion Convertible Preferred Stock (in shares)			(166)	(284.2638)	(190.0572)			27,434,704
Share-based compensation expense											355,642								355,642
Net loss												(34,257,370)							(34,257,370)
Foreign currency translation adjustment													3,275,948						3,275,948
Balances, Ending at Dec. 31, 2025								$ 2,974			$ 183,856,376	$ (108,076,316)	$ (587,039)	$ (299,128)					$ 74,896,867
Balances, Ending (in shares) at Dec. 31, 2025								29,743,516